A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II

Next Previous
Trial Profile

A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER II
  • Sponsors AbbVie

    • Most Recent Events

    • 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
    • 09 Jan 2017 Results of population pharmacokinetic analysis (n=600) from one phase II clinical trial (NCT00918255) and two phase III clinical trials (NCT01468207 and NCT01468233) assessing the effects of potential covariates on adalimumab pharmacokinetics, published in the Clinical Pharmacokinetics journal.
    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top